Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Limited has achieved a significant milestone with the first surgical use of its nerve repair product, Remplir™, in the United States, following FDA clearance. This marks a crucial step in penetrating the US$1.6 billion US nerve repair market, supported by a network of 14 specialist distributors. The successful surgery in Ohio highlights Orthocell’s commitment to expanding its market presence and driving sales growth, with expectations of increased revenue in the second half of 2025.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for tissue reconstruction and healing in dental and orthopedic applications, with products like Striate+™ and Remplir™. The company is expanding its market presence with a strong financial position and a focus on global distribution.
Average Trading Volume: 1,294,812
Technical Sentiment Signal: Buy
Current Market Cap: A$266.5M
See more data about OCC stock on TipRanks’ Stock Analysis page.